Private Equity Is Reshaping Physical Therapy. Here's What It Means for Independent Clinics.

TL;DR

• Platform-scale PT deals now trade at roughly 10x to 14x adjusted EBITDA, while small independent practices sell anywhere from 3x to 16x depending on size and timing.
• Platform deals are real and recent: Confluent Health, backed by private equity firm Partners Group, bought MOTION PT in 2023 at roughly 12.5x EBITDA, right at the top of the platform range.
• Selling to a PE-backed platform usually means a real payout, and it usually costs you clinical autonomy through productivity targets, visit-volume quotas, and template-driven documentation.
• Staying independent has its own price: weaker payer leverage, no scale economies on software and billing, and a thinner exit as you near retirement.
• The viable middle path is running as lean as a platform without giving up ownership, starting with your vendor stack.

The consolidation wave hitting outpatient PT

Private equity firms have spent the last several years buying up outpatient physical therapy at a pace that now touches almost every regional market. If you own an independent clinic, you have probably fielded a call from a broker or a platform's corporate development team, and if you haven't yet, you likely will. The buying is not slowing, and the math behind it explains why.

The valuation gap between a platform and a single clinic sets the terms of every conversation. Platform-scale deals, where a PE sponsor acquires an established multi-site group to serve as the base for further acquisitions, trade in the range of 10x to 14x adjusted EBITDA. A small independent practice sells for far less, typically somewhere between 3x and 16x EBITDA depending on size, payer mix, growth, and how competitive the local bidding is. That spread is the whole game. A platform buys your clinic at a low multiple and folds it into an entity that the market values at a high multiple, so your earnings are worth more the moment they sit inside the larger group.

Your leverage in that negotiation depends almost entirely on timing and size. A clinic with strong cash-pay volume, multiple locations, and clean books in a market where two or three platforms are actively competing will command the top of the range. A solo clinic with heavy Medicare dependence and no succession plan sells near the bottom, if it sells at all. The earlier you engage while a market is still fragmented, the more competing buyers you can put in the room. Once a platform has locked up the referral sources and the best clinicians in your area, your negotiating position weakens with every quarter.

The MOTION PT deal shows where this is heading. In 2023, Confluent Health, a multi-brand PT consolidator backed by the private equity firm Partners Group, acquired MOTION PT at a price reported around 12.5x EBITDA, a platform-grade multiple that put real money behind the roll-up thesis. That price signals two things worth sitting with. First, sponsors will pay a premium for a well-run regional group with commercial-heavy payer mix and clean management, not just any outpatient clinic. Second, a deal at that multiple rewards the exact profile aggregators say they want, which means every clinic that fits it in Confluent's target markets is a live prospect.

Read deals like MOTION PT as a template rather than a headline. Consolidators including Upstream Rehabilitation, Athletico, Ivy Rehab, and ATI Physical Therapy are past their initial platform-formation phase and are now doing selective tuck-ins in defined geographic clusters and specialty niches where a roll-up can dominate referrals. Sports medicine and pediatric therapy carry the strongest specialty premiums right now, and pelvic health is close behind, because a platform that owns most of the specialized capacity in a region can dictate terms to payers and referral partners alike.

None of this makes selling the right move or the wrong one. It makes the decision unavoidable. The independent clinic that treats consolidation as someone else's problem is still making a choice, just a passive one, and passive choices in a consolidating market tend to get made for you. The rest of this piece works through what actually changes when you sell, what you give up by staying out, and how to evaluate an offer with clear eyes before a term sheet ever reaches your desk.

What owners who sold are actually saying

Physical therapy owners who sold to private equity tend to fall into two camps in online discussion threads, and the split usually comes down to how much they cared about running the clinic versus cashing out of it. Both groups are worth hearing, because the offer that looks generous on paper reads very differently to an owner who wanted to keep practicing than to one who was already planning an exit.

The sellers who regret the deal almost always describe the same loss, which is control over how they treat patients. One owner on a private-practice thread wrote about watching required visit counts climb after the acquisition, with the platform pushing therapists to see more patients per hour than the owner had ever scheduled. Another described the shift to standardized documentation and productivity dashboards, saying the corporate side measured throughput while the clinical judgment that built the practice stopped counting for much. A common thread runs through these accounts. The money arrived, and then the job the owner loved changed into a job someone else designed.

The regret is sharpest for owners who stayed on after the sale expecting to keep leading. Earnouts and retention clauses often tie a chunk of the payout to hitting targets set by the new parent, so a seller who disagrees with the productivity model still has to work inside it for years. Several owners described the strange position of taking orders in a building they used to own, watching newer therapists burn out under ratios they never would have set themselves.

The owners who call it worth it usually had a different goal going in. Some were within a few years of retirement and saw no realistic buyer other than a platform, so the deal solved a succession problem that would otherwise have left them selling equipment at a loss. One poster who sold a two-location practice said the multiple he received was more than he could have saved in a decade of running lean, and he was honest that he had grown tired of payroll, credentialing, and payer fights. For him, handing off the administrative weight was the point, and the loss of clinical autonomy mattered less because he was ready to stop practicing anyway.

A smaller group lands in between, describing platforms that largely left the clinical model alone, at least early on. These owners tend to credit a specific factor, usually a management team that came from clinical backgrounds rather than pure finance, and they warn that the experience varies enormously by which firm and which platform does the buying. Their advice repeats across threads. Diligence the acquirer's existing clinics before you sign, and talk to therapists who already work inside them, because the term sheet tells you the price while those conversations tell you the job.

The honest takeaway from these accounts is that the trade is real in both directions. You are exchanging autonomy and daily control for liquidity and an exit, and whether that exchange feels like a win depends almost entirely on what you wanted the practice to be in the first place.

Life inside a PE-backed platform

The first change most clinics notice after joining a platform is a productivity target attached to the therapist, usually measured in visits per day or billable units per hour. Roll-up economics create that pressure directly. A private equity firm buys a group at a multiple of EBITDA, so every additional visit a therapist can absorb without adding staff raises the number the platform eventually sells for. A therapist who used to see ten or eleven patients a day may find the expectation moved to fourteen or sixteen, with the extra volume defended as normal for the market.

Staffing ratios shift for the same reason. Platforms lean on physical therapist assistants and aides to cover more patients per licensed therapist, because labor is the largest cost line and thinning it improves margin at scale. In practice, that changes what a treating therapist actually does during a session. You spend less time hands-on and more time supervising, moving between two or three patients running concurrent programs, and signing off on work you did not fully deliver yourself.

Documentation becomes the third pressure point, and it is where clinical discretion erodes most quietly. Platforms standardize charting across dozens or hundreds of sites so billing runs cleanly, audits pass, and any therapist can pick up any caseload. Standardization usually arrives as templates. You choose from prebuilt phrases and preset plan-of-care structures rather than writing the note the way you would reason through the case. The template speeds up billing and protects the platform in an audit, and it also flattens the individual clinical judgment that used to live in the record.

None of these mechanisms is hidden or unusual. Each one follows from the arithmetic of buying practices to sell them later at a higher multiple. Higher throughput, leaner staffing, and standardized documentation all raise EBITDA and make the platform easier to operate across many locations. The therapist experiences the sum of those three levers as a workday with less room to decide how a given patient should be treated.

The autonomy question is where sellers and buyers describe the same facts differently. Platform leadership frames productivity targets and templates as guardrails that keep quality consistent and the business fundable. A therapist who trained to individualize care often experiences the same guardrails as a ceiling on judgment. Both descriptions can be true at once, because the standardization that makes a fifty-site group manageable is the same standardization that removes the small daily choices a solo owner takes for granted.

What varies is how far a platform pushes. Some hold visit targets loose and treat documentation templates as a starting point a clinician can override. Others enforce units per hour strictly and route exceptions through regional management. That range is the single most important thing to understand before you sign, because the brand name on the door tells you almost nothing about which version you are joining. Two clinics under the same parent can run very differently depending on regional leadership and how aggressively the platform is chasing its next sale.

For an owner weighing an offer, the operational reality matters as much as the check. The payout is a one-time event. The productivity target, the staffing model, and the charting system are what you and your team live inside every day afterward.

What staying independent actually costs

Independent owners give up real leverage the moment they decide to stay out, and the biggest loss is at the negotiating table with payers. A PE-backed platform that controls forty clinics across a metro area walks into a contract negotiation with volume that an insurer cannot easily ignore. A single clinic negotiating alone takes the rate it is offered or walks away from a network it may need for referral flow. As platforms buy up market share, the remaining independents in that market negotiate from a weaker position every year.

Scale economics on infrastructure follow the same pattern. A platform spreads the cost of a billing team, a credentialing department, and a shared software stack across dozens of locations, so the per-clinic overhead drops as the group grows. A solo owner pays close to retail for the same billing software, the same clearinghouse fees, and the same scheduling tools, then absorbs the administrative work personally or hires for it out of a much thinner margin. The gap in cost per visit widens as the platform adds sites and the independent stays flat.

The succession problem is the one owners tend to notice last and regret most. A physical therapist who built a practice over twenty years often has most of their net worth tied up in a business that only a handful of buyers want, and the most active buyers are the PE-backed platforms doing the consolidating. If you wait until you are ready to retire to sell, you are negotiating from a position of need against a buyer who knows it. Owners who never plan an exit sometimes find the practice is worth far less to an outside party than the years of income it produced suggested.

These disadvantages compound as consolidation continues in a given market, which is what makes timing matter. Early in a roll-up, an independent still has referral relationships, patient loyalty, and a payer mix that a platform would pay a premium to acquire. Later, after the platform has captured the referral sources and squeezed the local rates, the same clinic is worth less and competes against a lower-cost operator down the street. The choice to stay independent is defensible, but it gets more expensive to defend the longer you wait to make it deliberately.

None of this argues that selling is the right move. It argues that staying independent carries a running cost, and that cost is not fixed. An owner who understands where the leverage, the scale gap, and the exit window actually sit can decide to stay out with open eyes, rather than discovering the price of that decision years later when the options have narrowed.

Before you sign a term sheet

The most important questions in a term sheet are about clinical control, not price, and most owners spend all their attention on the number. Before you engage on multiples, get answers in writing on who sets treatment protocols after close, who owns the documentation templates, and whether visit-volume targets are contractual or aspirational. A platform that says "nothing changes clinically" and then hands you a productivity dashboard three months later has not lied to you. It simply never put the dashboard in the contract, and you never asked.

Ask specifically how productivity gets measured and what happens when you miss the target. A visits-per-clinician-per-day number sounds harmless until you learn it's tied to bonus pools, staffing decisions, or your own continued employment. Push for the actual figure the platform uses at comparable clinics today, not the range in the pitch deck. If the buyer will not share real numbers from acquired practices, treat that as your answer.

Earnout structures are where good headline prices quietly shrink, and clawbacks are the sharpest edge. A clawback lets the buyer recover money already paid to you if post-close performance drops below a threshold, which means a rough year two can pull back what you banked in year one. Read the trigger conditions closely and model the downside case, not the base case. An earnout that only pays in full if the clinic grows 15 percent a year is a price cut dressed as an incentive.

Watch how every earnout metric is defined, because the definition decides who wins the disputes later. EBITDA can be adjusted a dozen ways, and the buyer usually controls the add-backs, the allocation of shared corporate costs, and the accounting calendar. Insist that the metric be defined with worked examples in the agreement, and that you get audit rights over the numbers used to calculate your payment. Vague definitions favor the party doing the math, and that party is not you.

Leadership retention triggers deserve the same scrutiny as the money. Many deals hold back a meaningful slice of the price against you or your key clinicians staying for a defined period, and the buyer often keeps the right to define "cause" for termination. If they can fire you for cause under a loose definition and cancel the retention payment, your earnout is theirs to void. Negotiate a tight, objective cause standard, and separate your retention money from performance metrics you no longer fully control after close.

Bring a healthcare M&A attorney and an accountant who have worked PE-backed PT deals specifically, not your general business lawyer. The buyer has closed dozens of these transactions and knows exactly which clauses owners skim. You are negotiating one deal, probably the only one of your career, against a team that does this for a living. The gap in experience is the real leverage imbalance, and paying for specialist advice is the cheapest way to narrow it.

Is independence financially sustainable?

Staying independent only works as a strategy if you have run the numbers, and most owners haven't. Reimbursement math punishes inertia in a way it didn't a decade ago. Medicare's physician fee schedule has cut physical therapy payment rates in real terms for several consecutive years, and commercial payers rarely improve rates for a solo clinic with no volume to negotiate against. If your per-visit revenue is flat and your costs are climbing, the gap widens every quarter whether or not you make a single decision.

Three cost lines drive that gap, and each one moves in the wrong direction. Staffing is the largest. New-graduate physical therapist salaries have risen sharply as demand outpaced supply, and a clinic that can't match a hospital or PE-backed platform on pay loses hires it spent months recruiting. Administrative overhead is the quiet one. Billing, credentialing, prior authorization, and compliance work all scale with payer complexity, not with your patient volume, so a two-therapist clinic carries nearly the same back-office burden as a five-therapist one. Rent, software, and equipment fill out the rest, and none of them fall.

To stress-test your own position, start with a single number. Calculate your contribution margin per visit, meaning revenue per visit minus the direct cost of delivering it. Then subtract your fixed monthly overhead divided by your visit count. If that figure has shrunk over the past three years, project it forward under flat reimbursement and a 3 to 5 percent annual cost increase. The line tells you how many quarters you have before margin turns negative at your current volume. Owners who run this often find they have less runway than they assumed.

That projection reframes the decision. Staying independent because selling feels like defeat is not a plan, and the market no longer rewards owners who treat independence as a default. A clinic that decides to stay out needs a concrete answer to how it will hold margin as rates stagnate. That usually means growing visit volume without adding proportional overhead, tightening the cost of care per visit, or building a referral base that gives you actual leverage with at least one payer. Absent one of those levers, the passive choice to stay independent is a slow version of the outcome you were trying to avoid.

The point is not that independence fails. Plenty of clinics hold healthy margins by controlling cost per visit and keeping their schedules full. The distinction is between owners who stay independent because they modeled it and built toward it, and owners who stay independent because deciding felt harder than drifting. Only the first group tends to still be independent in five years.

Competing lean: the technology lever independents have

The advantage a PE-backed platform buys is efficiency, not clinical quality, and efficiency is the one thing an independent owner can copy without selling. A roll-up wins on cost per visit by spreading billing, scheduling, and software across dozens of sites. A solo clinic or a two-location group can close most of that gap by consolidating its own vendor stack, which is far cheaper and faster than most owners assume.

Start with what the platform standardizes, because those are the same line items draining an independent's margin. Scattered tools cost more than money. When your billing system, your scheduling software, and your patient engagement app do not talk to each other, your front-desk staff becomes the integration layer, and their time is your most expensive input. Consolidating onto fewer platforms that share data removes that manual reconciliation and gives you the reporting a platform's regional director takes for granted.

Patient engagement is where the gap looks widest and closes fastest. PE platforms invest in home exercise adherence because it drives outcomes, reduces cancellations, and produces the documentation payers increasingly ask for. An independent clinic reaches the same standard through a platform like Physitrack, which delivers home exercise programs, tracks real adherence rather than logins, and handles patient messaging and outcome measures in one app. You get the engagement infrastructure of a large network on a per-clinician subscription, without the enterprise IT budget or the ownership change that funds it.

Running lean does not mean matching a platform's productivity targets. It means removing the administrative drag those targets exist to overcome, so you keep your visit standards and your margins at the same time. The platform hits its number by pushing therapists harder. You hit yours by making each therapist's non-clinical hour cheaper, which is a tool problem, not a staffing one.

The decision an owner actually faces is not sell or survive. It is whether to run the clinic as deliberately as a platform would run it, on your terms and with your name on the equity. A clinic that consolidates its stack, tracks adherence, and reports outcomes is worth more whether you eventually sell or keep it for another twenty years. Independence stops being the passive default and becomes a position you can defend, because you have closed the efficiency gap that made selling look inevitable.

What this means for your clinic

The sell-or-stay decision has stopped being hypothetical for most independent owners. Brokers are calling, platforms are consolidating your local market, and the reimbursement pressure that made selling attractive last year has not eased. You will make this decision, either actively or by letting the market make it for you.

Selling can convert years of practice-building into a real payout, and it can also hand your clinical decisions to a productivity model you did not design. Staying independent protects your autonomy, and it leaves you carrying scale disadvantages on payer rates, billing infrastructure, and eventual exit. Neither path is obviously right, which is exactly why the choice deserves more than a gut reaction to a term sheet.

If you decide to stay, treat that as a strategy, not a default. Run the numbers against stagnant payer rates and rising staffing costs, tighten your vendor stack so your overhead looks more like a platform's, and build the succession plan that consolidation will otherwise dictate for you. The owners who keep their independence and their sanity are the ones who chose it deliberately and ran lean enough to make it pay.